|Day Low/High||86.90 / 87.01|
|52 Wk Low/High||19.62 / 87.01|
Juno Therapeutics, Inc. (NASDAQ:JUNO) today announced the closing of its initial public offering of 12.
The power to control drug prices in the U.S. now has shifted firmly to cost-cutting insurance carriers and pharmacy benefit managers and away from biotech and drug companies.
Cramer will be watching for existing home sales data, Walgreen's earnings and Santa's sleigh.
Juno Therapeutics CEO Hans Bishop tells TheStreet's Jill Malandrino that the company is focused on improving cancer patients' treatment.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.